Intelligence Feed event · Equity · 2026-09-09

    CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M

    Question

    CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M

    Direct answer

    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with revenue rising 78% quarter-over-quarter to $76 million. Uptake was supported by FDA label expansion extending treatment eligibility to pediatric patients aged 2 and above, broadening the addressable patient population for blood disorder indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-reports-78-percent-qoq-casgevy-sales-growth-to-76m-512f22

    EQUITY
    CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with revenue rising 78% quarter-over-quarter to $76 million. Uptake was supported by FDA label expansion extending treatment eligibility to pediatric patients aged 2 and above, broadening the addressable patient population for blood disorder indications.
    CRSPVRTX
    Impact
    65
    SEP 9
    SIG
    90%
    CRSPVRTX
    CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with revenue rising 78% quarter-over-quarter to $76 million. Uptake was supported by FDA label expansion extending treatment eligibility to pediatric patients aged 2 and above, broadening the addressable patient population for blood disorder indications.
    → A 78% sequential increase in Casgevy commercial revenue and pediatric label expansion accelerates CRISPR's path to operational cash-flow breakeven.
    Impact
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with revenue rising 78% quarter-over-quarter to $76 million. Uptake was supported by FDA label expansion extending treatment eligibility to pediatric patients aged 2 and above, broadening the addressable patient population for blood disorder indications.
    Affected
    CRSPVRTX
    Transmission
    A 78% sequential increase in Casgevy commercial revenue and pediatric label expansion accelerates CRISPR's path to operational cash-flow breakeven.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial product revenue ramp and addressable market expansion via pediatric labelUp1-4wCasgevy revenue grew 78% QoQ to $76 million with FDA pediatric approval.
    VRTXcommercial collaboration revenue share on Casgevy distributionUp1-4wVertex partners with CRISPR on Casgevy commercialization.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month